Baclofen bridging, weaning protocol and pain management of a person with T6 paraplegia who required removal of intrathecal baclofen pump due to wound infection

2021 ◽  
Vol 14 (9) ◽  
pp. e242686
Author(s):  
Jessica Roth ◽  
Hayder Agha ◽  
Charlotte Davis

Intrathecal baclofen is recognised as an effective treatment option for severe symptoms of segmental spasticity after spinal cord injury. We present our experience of a case of a patient who was admitted to our centre for elective intrathecal baclofen pump revision surgery, but postsurgical complications of a blocked catheter and subsequent wound infections meant the pump had to be removed. In this case, treatment of severe spasticity and nociceptive pain was required while avoiding potentially lethal side effects of sudden baclofen withdrawal. We suggest an effective bridging and weaning protocol for oral drug titration to treat spasticity and pain as a blended syndrome in this challenging situation.

2021 ◽  
pp. 76-78
Author(s):  
Anand Sharma ◽  
Yashbir Dewan

Management of severe spasticity following penetrating brain injury is often a difcult problem. Orally administered medications generally offer limited benets. Intrathecally administered baclofen has been shown to be effective in patients with spasticity caused by spinal cord injury and stroke, however, the effectiveness of ITB for spasticity related to penetrating brain injury is not well established. We reported two cases of spastic hypertonia following gunshot injury to brain with brief review of literature upon role of intrathecal baclofen pump (ITB) in cortical spastic hypertonia


2008 ◽  
Vol 31 (1) ◽  
pp. 97-102 ◽  
Author(s):  
Michael L. Jones ◽  
Donald P. Leslie ◽  
Gerald Bilsky ◽  
Brock Bowman

2010 ◽  
Vol 121 (7) ◽  
pp. e27
Author(s):  
Katsuhiro Mizuno ◽  
Kazushige Hasegawa ◽  
Osamu Uemura ◽  
Daisuke Matsuura ◽  
Masako Katahira ◽  
...  

1993 ◽  
Vol 78 (2) ◽  
pp. 226-232 ◽  
Author(s):  
Robert J. Coffey ◽  
David Cahill ◽  
William Steers ◽  
T. S. Park ◽  
Joe Ordia ◽  
...  

✓ A total of 93 patients with intractable spasticity due to either spinal cord injury (59 cases), multiple sclerosis (31 cases), or other spinal pathology (three cases) were entered into a randomized double-blind placebocontrolled screening protocol of intrathecal baclofen test injections. Of the 88 patients who responded to an intrathecal bolus of 50, 75, or 100 µg of baclofen, 75 underwent implantation of a programmable pump system for chronic therapy. Patients were followed for 5 to 41 months after surgery (mean 19 months). No deaths or new permanent neurological deficits occurred as a result of surgery or chronic intrathecal baclofen administration. Rigidity was reduced from a mean preoperative Ashworth scale score of 3.9 to a mean postoperative score of 1.7. Muscle spasms were reduced from a mean preoperative score of 3.1 (on a fourpoint scale) to a mean postoperative score of 1.0. Although the dose of intrathecal baclofen required to control spasticity increased with time, drug tolerance was not a limiting factor in this study. Only one patient withdrew from the study because of a late surgical complication (pump pocket infection). Another patient received an intrathecal baclofen overdose because of a human error in programming the pump. The results of this study indicate that intrathecal baclofen infusion can be safe and effective for the long-term treatment of intractable spasticity in patients with spinal cord injury or multiple sclerosis.


2009 ◽  
Vol 146 (1-2) ◽  
pp. 106-110 ◽  
Author(s):  
Markus Kofler ◽  
Katharina Poustka ◽  
Leopold Saltuari

Sign in / Sign up

Export Citation Format

Share Document